The Medical Letter on Drugs and Therapeutics
Choice of an Oral Anticoagulant in Atrial Fibrillation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Atrial fibrillation increases the risk of thromboembolic stroke. Anticoagulant therapy can reduce this risk and is recommended for patients with atrial fibrillation and one or more of the following: congestive heart failure, hypertension, age ≥75 years, diabetes, or prior stroke or transient ischemic attack (CHADS2 score ≥1).1

For many years, the vitamin K antagonist warfarin (Coumadin, and generics) has been the oral anticoagulant of choice for prevention of thromboembolic stroke in patients with atrial fibrillation.2,3 The approval of 2 new oral anticoagulants in recent years has provided additional options for such patients. These new agents have been studied only in patients with nonvalvular atrial fibrillation.

WARFARIN — Warfarin can cause major bleeding, including intracranial hemorrhage. Other ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Choice of an Oral Anticoagulant in Atrial Fibrillation
Article code: 1400b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian